[2018 Round-up] Movement disorders in 2018: tackling this evil at the roots

In 2018, several initiatives that have aimed to slow progression or prevent development of movement disorders have provided encouraging results. In mouse models of Parkinson's disease, drugs that activate glucagon-like peptide 1 (GLP-1) receptors have been shown to target neuroinflammation, reduce microglial activation following exposure to aggregated α-synuclein, and prevent microglial-mediated conversion of astrocytes to a neurotoxic phenotype.1 Mild improvements of motor scores in patients with Parkinson's disease who were treated with the GLP-1 receptor agonist exenatide compared with placebo2 need to be confirmed in other studies (NCT02953665 for liraglutide, NCT03659682 for semaglutide).

Your comment

You are not allowed to add comments!


No comments found!

Select Language

ICNApedia Community Pages

Journal of the International Child Neurology Association

icnapedia vle

ICNC2018 Mumbai India